TapImmune Inc. (OTCMKTS:TPIV) Falls On Its Face Again

For three consecutive sessions TapImmune Inc. (OTCMKTS:TPIV) looked like it had finally found its place on the charts, but then yesterday saw it pushed 7.14% down, in spite of the fact that some information on its activities finally hit the web.

Dr. Glynn Wilson, TPIV CEO and Chairman had a lot of positive things to say, and did so in the interview he gave. However, it is likely that investors didn’t find the plan to “start off these two programs, starting at the end of this year with the Phase II program” all that appealing – and that’s completely understandable.

After all, it showed investors how slowly TPIV‘s plan will unfold – which is an unpleasant realization, as it has multiple unpleasant implications. The company’s latest financial reports showed that it has some serious cash on hand to fund its operations. However, said 10-Q also revealed the fact that TPIV is racking liabilities and loss at a staggering rate – so it’s unclear exactly how long that $3.1 million will last.

This, in turn means, that the company likely will soon be forced to depend on funding from third parties to finance its research. Judging by the company’s history to date, it looks likely that said funding will be achieved through the issuance of convertible notes – and a lot of them, at that. Needless to say, this will put investor value in peril of even more dilution.

And TPIV investor value has suffered more than enough toxic dilution as it is. Suffice it to say that less than 8 months ago, TPIV had little more than 20 million shares issued and outstanding. As of August 16, 2015 that amount had reached 46 million, due to issuance of stock at severely discounted prices.

Investors should definitely take these possibilities into consideration when making up their mind about committing to TPIV stock.